Naox Technologies SAS secured U.S. FDA 510(k) clearance for Naox Link, its in-ear electroencephalography (EEG) device for clinical use both at home and in health care settings. Naox Link is a pair of earbuds the company hopes will transform how the brain activity is monitored, helping diagnose and track a number of conditions affecting the brain.
Nia Therapeutics Inc. reported data from an in vivo study of its Smart Neurostimulation System, an AI-based brain-computer interface (BCI), which demonstrated its ability to perform chronic sensing, neural-state decoding and programmable stimulation.
Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and Vigonvita Shanghai Co. Ltd. have described NMDA and serotonin receptor antagonists reported to be useful for the treatment of neurological disorders.
Jumpcan Pharmaceutical Group Ltd. has divulged sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Haisco Pharmaceutical Group Co. Ltd. has synthesized G protein-coupled receptor GPR52 agonists reported to be useful for the treatment of psychiatric disorders.
Researchers at Case Western Reserve University and their collaborators described the use of P7C3-A20, a compound that restores nicotinamide adenine dinucleotide (NAD+) homeostasis, as a potential strategy to reverse Alzheimer’s disease (AD) pathology in advanced Aβ- and tau-driven AD models.
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive neurodegenerative disorder caused by a CAG repeat expansion mutation in the coding region of the ATXN2 gene, which encodes ataxin-2.
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
On the last day of the year, shares of Axsome Therapeutics Inc. rose 22% on news that the U.S. FDA accepted and granted priority review of the company’s supplemental NDA for AXS-05 to treat Alzheimer’s disease agitation, a $1 billion-plus opportunity, scheduling the PDUFA date for April 30.
RSS
